Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

[1]  Jiangtao Gao,et al.  Chemistry and biology of kahalalides. , 2011, Chemical reviews.

[2]  E. Espinosa,et al.  Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. , 2009, European journal of cancer.

[3]  R. Salazar,et al.  Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[4]  G. Faircloth,et al.  Kahalalide F and ES285: potent anticancer agents from marine molluscs. , 2006, Progress in molecular and subcellular biology.

[5]  G. Giaccone,et al.  Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling , 2005, Molecular Pharmacology.

[6]  T. D. de Reijke,et al.  Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer , 2005, Clinical Cancer Research.

[7]  J. Schellens,et al.  Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. , 2004, Biomedical chromatography : BMC.

[8]  K. Rinehart,et al.  Progress in the clinical development of new marine-derived anticancer compounds. , 2004, Anti-cancer drugs.

[9]  Y. Suárez,et al.  Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. , 2003, Molecular cancer therapeutics.

[10]  J. Schellens,et al.  Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. , 2002, Journal of mass spectrometry : JMS.

[11]  Fernando Albericio,et al.  Synthesis and Structure Determination of Kahalalide F1,2 , 2001 .

[12]  E. Giralt,et al.  Synthesis and structure determination of kahalalide F (1,2). , 2001, Journal of the American Chemical Society.

[13]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[14]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[15]  J N Weinstein,et al.  Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. , 1997, Journal of the National Cancer Institute.

[16]  M. Hamann,et al.  Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp. , 1997 .

[17]  M. Hamann,et al.  Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1). , 1996, The Journal of organic chemistry.

[18]  J. Ávila,et al.  The antitumoral compound Kahalalide F acts on cell lysosomes. , 1996, Cancer letters.

[19]  M. Hamann,et al.  Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp , 1993 .

[20]  D. V. Von Hoff,et al.  The human tumor cloning assay in cancer research and therapy: a review with clinical correlations. , 1985, Current problems in cancer.